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Clinical utility of remote platelet function measurement using P-selectin:
assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders
Philip M Bath, Jane May, & Stan Heptinstall
Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
Abstract
Vascular diseases such as myocardial infarction and ischemic stroke are associated with
increased platelet function whilst the risk of recurrence is reduced by antiplatelet agents
such as aspirin, clopidogrel, and prasugrel. However, some patients exhibit high platelet
reactivity, especially with clopidogrel. Existing platelet function tests may not be ideal in that
they can be expensive, are often time consuming, and measurements must be made near to
the patient and within a few hours of blood collection. Platelet activation leads to translocation
of P-selectin from alpha-granules to the cell surface. Following activation with arachidonic acid
(which is blocked by aspirin) or adenosine diphosphate (inhibited by clopidogrel) and fixation,
samples may be stored or posted to a laboratory performing flow cytometric quantification of
platelet P-selectin expression. Acute myocardial infarction and ischemic stroke are associated
with high platelet reactivity on clopidogrel in 6–58% of patients when assessed with P-selectin
expression, and high reactivity was associated with an increased risk of recurrence after
myocardial infarction. Use of P-selectin expression tests may also be of relevance to surgical
and veterinary practice and the diagnosis of mild bleeding disorders. The present review
explores this topic in further detail.
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Platelets are small circulating anucleate cells that comprise the
main component of particulate hemostasis (1). Their key role in
stopping bleeding means that low numbers or platelet dysfunction
increases the risk of bleeding. Conversely, accentuated platelet
function, as occurs in the presence of vascular risk factors such as
hypertension and hyperlipidemia, contributes to acute coronary
syndromes and stent thrombosis. As a result, antiplatelet agents
such as aspirin and clopidogrel are used widely to reduce the risk
of recurrent vascular events (2–4).
In view of the relationship between reduced or accentuated
platelet function and subsequent disease and clinical events, mul-
tiple approaches have been developed to assess platelet function.
Extremely low number of platelets (thrombocytopenia, as occurs
in terminal leukemia) or high numbers (thrombocythemia, a mye-
loproliferative disorder) are easily detected using automated
hematology cell counters. Physiologically, platelet size and
count are inversely related, and size can be measured using the
same cell counters. Small low-function platelets are seen in term-
inal marrow failure, and large platelets are present and prognostic
after acute myocardial infarction and ischemic stroke (5,6).
However, these assessments of physical platelet parameters are
indirect measures of function, and direct assessments have been
developed. Historically, measurement of aggregation in platelet-
rich plasma predominated in research studies. This was not ideal
in that the approach is time consuming, needs significant techni-
cal support, and measurements must be made near to the patient
and within a few hours of blood collection.
Over the last 15 years, semi-automated “bedside” commercial
tests have been developed that reduce time and operator depen-
dence. Notable devices include Multiplate, VerifyNow, and
Biocytex VASP (7–9) and these assays are promoted in an inter-
national consensus for platelet function testing in patients on dual
antiplatelet therapy (10). Nevertheless, the cost of these devices
and their cartridges is relatively high, concordance between their
results is not high (7,11), and measurements must be made near to
the patient and within a few hours of venepuncture. Hence, the
addition of a diagnostic requiring no capital investment that
involves local blood sampling but with the flexibility provided
by remote measurement is potentially a welcome addition to the
armamentarium of measuring platelet function.
P-selectin
P-selectin (CD62P) is a protein that functions as a cell adhesion
molecule on the surface of activated platelets and endothelial
cells. In both cell types, P-selectin is stored in alpha-granules
and is translocated to the cell surface following cell activation.
In platelets, activation is driven by stimulation by vascular ago-
nists such as thrombin, collagen, adenosine diphosphate (ADP),
thromboxane A2, and its mimetics and inflammatory agonists
including interleukin-4. The relationship between circulating
soluble P-selectin and vascular diagnoses and outcomes is well
described, for example, in stroke (12), and reflects both platelet
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and endothelial function. In contrast, measurement of P-selectin
on the platelet surface assesses the extent of platelet activation
and expression changes in response to the same agonist(s) that
cause platelets to aggregate together. One role for P-selectin on
activated platelets is that it binds to a specific receptor, P-selectin
glycoprotein ligand-1, which is expressed on most leucocytes
(neutrophils, monocytes, lymphocytes, eosinophils), thus facilitat-
ing platelet–leucocyte conjugation.
Remote assessment of platelet function with P-selectin
Measurement of the surface expression on platelets of P-selectin
provides an alternative approach to assessing platelet function and
standardized tests are now available for a number of different
purposes (Platelet Solutions Ltd., PSL). Blood is taken by con-
ventional venepuncture, placed in warmed reaction tubes (13),
stimulated with selected agonist(s) (which leads to expression of
P-selectin onto the surface of platelets), fixed with PAMFix (14),
posted to a core laboratory, and surface P-selectin measured using
flow cytometry (15). One agonist is arachidonic acid (AA), the
effects of which are blocked by aspirin (aspirin test). The clopi-
dogrel test detects whether P2Y12 antagonists such as clopidogrel,
prasugrel, and ticagrelor prevent ADP stimulation of platelets. By
comparing data obtained using a number of different agonists,
information on the presence of platelet dysfunction or inhibition
in an individual can be obtained. Fixation prevents both platelet
aggregation and platelet–leucocyte conjugate formation so that all
activated single platelets are available for analysis.
In a comparison with light transmission aggregometry,
Multiplate, VerifyNow, and Biocytex VASP, the P-selectin-
based aspirin and clopidogrel tests were at least as effective in
determining the inhibitory effects of antiplatelet therapies includ-
ing combined aspirin and clopidogrel, and combined aspirin and
prasugrel (16). But what does differentiate assessment of platelet
expression of P-selectin from these other tests is that samples may
be sent by post from where the patient is (hospital, general
practice, home) to a core laboratory for measurement, results
can then be returned the next day. The test is stable for at least
28 days (9) (and possibly 35 days (17)) allowing between-country
as well within-country measurements. This approach is similar to
the measurement of other vascular risk factors such as blood
cholesterol.
Measurement of platelet expression of P-selectin may be com-
bined with other platelet assessments. For example, P-selectin and
CD63 (a marker of dense body secretion) may be assessed on
activated platelets in patients with enhanced bruising to diagnose
mild bleeding disorders (18).
Resistance
Although antiplatelet agents are highly effective at reducing the
risk of recurrent vascular events, a significant minority of patients
(≥35%) do not respond adequately to clopidogrel (19–28), a
similar but lesser problem also exists for aspirin (8,19,21,23,29).
High residual platelet reactivity whilst on treatment (HRPR,
amounting to resistance or nonresponse) can follow failure to
take or absorb the tablets, or to convert the drug into its active
metabolite, or for the metabolite to inhibit platelet function, i.e., a
mix of patient, drug, and genetic-related factors. It is widely
assumed that nonresponse means that antiplatelet therapy will
have only a limited effect on reducing vascular events (antiplatelet
failure); hence, patients with HRPR are in essence taking an
ineffective medication and so remain at increased risk of recurrent
events. Evidence for this comes from a substudy of the clopido-
grel in high-risk patients with Acute Non-disabling
Cerebrovascular Events trial that showed that the combination
of aspirin and clopidogrel was superior to aspirin alone in pre-
venting recurrence after minor ischemic stroke or TIA. However,
the presence of the CYP2C19 loss-of-function allele was asso-
ciated with a failure for clopidogrel to add to aspirin in preventing
recurrence (30). Around 14% of patients are CYP2C19-poor
metabolizers. A key reason for testing platelet function is to
identify patients who exhibit HRPR.
Proton pump inhibitors
Drug interactions are common with antiplatelet agents.
Clopidogrel is a prodrug that requires activation by cytochrome
P450 (especially CYP2C19) to form an active metabolite.
Initially, there was concern that gastroprotection with proton
pump inhibitors, which can inhibit CYP2C19, should be avoided.
This advice was attenuated to suggesting that omeprazole and
esomeprazole should be avoided. A recent meta-analysis found
that the PPI–clopidogrel interaction seen in vitro has no clinical
significance (31). Rather, patients taking PPIs are likely to have
more comorbidities and therefore a higher vascular risk. As a
result, there is no clinical role for monitoring platelet function
when patients are taking clopidogrel and a PPI.
Clinical studies
Volunteers
Several studies have been reported in normal volunteers as part of
the development of the aspirin and clopidogrel P-selectin tests
(15,32). These show the utility of the aspirin test for assessing
aspirin with suppression of AA-stimulated P-selectin expression.
Similar findings have been made for the clopidogrel test for ADP-
stimulated P-selectin.
Myocardial infarction
Platelets are activated in acute myocardial infarction and chroni-
cally afterward and in procedures such as angioplasty and stent
insertion. Antiplatelet agents such as aspirin, clopidogrel, and
prasugrel are effective in reducing the risk of recurrent events
(3,4). In a study of 100 patients with acute coronary syndrome
and who were on combined aspirin and clopidogrel, the clopido-
grel test found that a majority of patients had a high on-treatment
platelet reactivity (Table I) (33). In patients who went on to
develop a further cardiovascular event (cardiovascular death, non-
fatal myocardial infarction, or stent thrombosis) during the fol-
lowing 12 months, the P-selectin levels were higher than in
patients who had no further event. All patients had a suppressed
aspirin test and there was no difference in aspirin-related
P-selectin expression between patients who developed, or did
not develop, a subsequent cardiovascular event (Table I) (33).
In a further study of patients with recent ACS (34), ADP-
stimulated P-selectin expression (clopidogrel test) was measured
1 month after starting clopidogrel or prasugrel. HRPR was higher
in those taking clopidogrel than those on prasugrel (Table I).
However, P-selectin levels were higher in prasugrel users if they
had hypertension than if they did not.
A comparison of clopidogrel and prasugrel was made in
another study of patients with ACS (9). Prasugrel treatment
resulted in significantly greater inhibition than clopidogrel.
Three patients with very high P-selectin values were subsequently
found to be not taking prasugrel. Additionally, three patients had
high AA-stimulated high P-selectin expression and were either
nonresponders to aspirin or more likely not taking this drug (9).
426 P. M. Bath et al. Platelets, 2018; 29(5): 425–430
Stroke
Platelets are activated in acute stroke and chronically afterward,
and antiplatelet agents such as aspirin, clopidogrel, and dipyrida-
mole are effective in reducing the risk of recurrence (4,35,36).
The effect of aspirin and clopidogrel on platelet expression of
P-selectin was assessed in the large Triple Antiplatelets for
Reducing Dependency after Ischaemic Stroke (TARDIS) trial;
TARDIS compared the effect of intensive (combined aspirin,
clopidogrel, and dipyridamole) versus guideline (combined
aspirin and dipyridamole, or clopidogrel alone) in patients with
acute stroke or transient ischemic attack (37,38). At baseline, the
aspirin test identified patients who declared that they had been
taking this antiplatelet before randomization; HRPR was present
with aspirin in only 4.7% of patients (Table I) (39,40). Whilst the
clopidogrel test similarly identified patients saying that they had
been taking this drug, 24.7% of them did not have suppressed
platelet expression of P-selectin (39,40). For so-far unexplained
reasons, the presence of a second antiplatelet was associated with
higher P-selectin expression than if only one antiplatelet, e.g.,
AA-stimulated P-selectin (aspirin test) was higher in patients
taking combined aspirin and clopidogrel than aspirin alone
(Table I). The effects of randomized treatment on P-selectin
expression and relationship between P-selectin levels and subse-
quent stroke recurrence and bleeding are to be analyzed.
In the Pre-Accrist study, 62 patients with recent stroke and
who were taking clopidogrel were studied; minority were also
Table I. Characteristics of patients and platelet P-selectin expression in response to antiplatelet agents.
Subjects Study N
Age
(years)
Female
(%) Antiplatelet Clop test
Nonresponse
(%) Asp test
Nonresponse
(%)
Normal Fox (15) 62 None 816 (247) >500 (90) 950 (295)
14 Clop 301 (94) –
12 Asp + Clop 306 (81)
Fox (32) 14 None 866 (197)
14 Clop 293 (103)
10 Asp + Clop 326 (123)
ACS Fox (15) 30–42 Asp + Clop 638 (246) 86 (63) >300 (3)
Thomas (33) 100 67 (–) 37 Asp + Clop >860 (58) >500 (0)
88 Asp + Clop
[1]
777 (281) 95 (56)
12 Asp + Clop
[2]
953 (246) 100 (35)
Laohathai (34) 47 Clop [3] 606 [402]
23 Clop [4] 543 [396]
43 Pras [3] 356 [161]
28 Pras [4] 463 [234]
May (9) 102 Asp + Clop 621 (241) 161 (153) 3
56 Asp + Pras 397 (149) 91 (34)
IS/TIA TARDIS (40) 108 66 (10) 30 None 983 (316) >860 (66) 509 (448) >500 (35)
418 69 (10) 36 Asp 944 (298) >860 (59) 198 (172) >500 (3)
42 70 (11) 34 Asp + Dip 1139 (388) >860 (78) 296 (269) >500 (12)
54 69 (11) 35 Clop 578 (276) >860 (17) 578 (276) >500 (70)
33 71 (10) 38 Clop + Asp 758 (296) >860 (36) 256 (227) >500 (12)
Pre-ACRIST
(41)
46 64 (14) 47 Clop 534 (273) >860 (14) 640 (332) >500 (59)
16 Asp + Clop 377 (232) >860 (6) 446 (308) >500 (38)
Surgery Keeler pre-op
(43)
87 67 [20] 44 None 1303 [397]
20 74 [11] 30 Asp 77 [50]
Keeler per-op
(43)
87 None 1224 [552]
20 Asp 282 [836]
Endovascular
coiling
74 52 77 Asp + Clop 530 (208) >860 (8) 110 (116) >500 (1)
Bleeding Dovlatova (18) 41 None <900 (5) <1007 (5)
9 79 Granule
defect
<900 (56) <1007 (100)
3 “ TXA2 defect <900 (67) <1007 (67)
14 “ GI defect <900 (50) <1007 (57)
Animals, dogs Dunning (44) 39 None 954 (634) 1063 (644)
1 Asp 2992 (–) 2216 (–)
3 Clop 278 (30) 964 (600)
2 Asp + Clop 173 (7) 395 (127)
ACS: Acute coronary syndrome; Asp: aspirin; Clop: clopidogrel; GI: GI signaling defect; Granule: dense granule defect; IS: ischemic stroke;
Pras: prasugrel; TIA: transient ischemic attack; TXA2: thromboxane A2 defect.
[1] No subsequent vascular event.
[2] Subsequent vascular event.
[3] Without hypertension.
[4] With hypertension.
Nonresponse columns show cut-point for nonresponse and percentage of non-responding subjects; the cut-point detects patients with high platelet
reactivity (if on an antiplatelet) or low platelet reactivity (if a bleeding disorder). Data are mean (standard deviation) or median [interquartile range].
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taking aspirin. Twenty-three percent of patients did not have
suppressed levels for the clopidogrel test (41).
At one neuroscience center, the clopidogrel test is being used
off-label to identify nonresponse to clopidogrel in patients having
coiling of cerebral aneurysms (42), such patients are changed to
prasugrel prior to the procedure if they appear to have HRPR on
this P2Y12 antagonist (Table I). The use of the test is exemplified
in one patient who had unsuppressed P-selectin expression on the
aspirin test, the test suppressed when the patient became compli-
ant of medication.
Surgery
Many older patients take aspirin regularly for vascular (or cancer)
prophylaxis. The question then arises as to whether this should be
stopped temporarily before major surgery to prevent the perceived
risk of increased operative blood loss. In an observational study,
the effect of stopping aspirin preoperatively in 20 patients having
colorectal surgery was assessed and compared with a group who
were not on aspirin (43). P-selectin expression was lower on
aspirin (Table I) and within 5 days of stopping aspirin prior to
surgery. The aspirin test showed that P-selectin expression rose
with the length of time between stopping aspirin and surgery.
Although the proportion of patients with a complication, includ-
ing those with hemorrhage, was higher in the aspirin group,
P-selectin expression was not associated with complications or
bleeding (43).
Veterinary medicine
One study assessed whether P-selectin expression could be used
to measure platelet function in dogs (44). The relevance is that
pets are increasingly given antiplatelet drugs to prevent vascular
disease. Using antibodies against canine P-selectin, it was possi-
ble to measure platelet function and the inhibitory effects of
antiplatelet agents (Table I). A study is ongoing in cats.
Bleeding disorders
The above clinical disorders all share the use of P-selectin to
assess the inhibitory effects of antiplatelet agents. However,
P-selectin expression may also be used to diagnose mild bleeding
disorders (45) such as defects in dense granule secretion, throm-
boxane A2 pathway, GI signaling, response to collagen, or
response to thrombin receptor activating peptide (18). The results
were comparable to light transmission aggregometry/lumiaggre-
gometry (Table I), a time- and labor-intensive technique that has
to be performed shortly after venepuncture.
Clinical P-selectin measurements
The table summarizes results from clinical studies in normal
volunteers, patients with vascular or hematological disorders or
those having surgery, and in dogs. Whilst comparisons between
studies are difficult using summary data, the following observa-
tions may be made.
The clopidogrel test is sensitive to the presence of ADP
receptor antagonists such as clopidogrel and prasugrel.
Typically, volunteers or patients who are not on an antagonist
exhibit values above 800 units whilst those on clopidogrel have
expression levels below 700 units. Limited data suggest that
prasugrel lowers expression more than clopidogrel. Using a pre-
defined cutoff of 860 units (33), a significant proportion of
patients on clopidogrel do not suppress (i.e., high platelet reactiv-
ity whilst on treatment), this ranging between 6% and 36% (with
one study finding it as high as 58% (33)).
The aspirin test showed that individuals who were taking this
inhibitor of cyclooxygenase typically had P-selectin expression
below 500 units (and often <200 units) whilst those not taking
aspirin usually exceeded 500 units (and often >900 units). High
platelet reactivity (using a cutoff of >500 units) was uncommon
on aspirin, typically affecting <5% individuals.
Future prospects
Use of remote P-selectin measurement offers great promise but
several important questions remain. First, P-selectin expression
varies considerably between individuals and a key question is
what values should be used for deciding that a patient has high
platelet reactivity if on an antiplatelet or a low value in the
presence of bleeding. Typically, cut-points need to be defined
by outcome data so that patients with a value on one side of the
cut-point are much more likely to have an event than if on the
other side. Practically, this means defining the cut-point using one
set of data and then testing it using a second data source. To date,
the only cut-point to be defined in this way is the value of >860
units for the clopidogrel test which signals high platelet reactivity
on clopidogrel (33).
Second, predictors of high platelet reactivity on clopidogrel
need to be identified. It is likely that high platelet reactivity on
treatment will be associated with increasing age, male sex, pre-
sence of vascular risk factors such as hypertension and diabetes
mellitus, and having an acute vascular event. Although a study of
patients with acute coronary syndrome found no such difference
(33), it was small and the comparisons were probably under-
powered statistically.
Third, the relationship between P-selectin expression and out-
come needs to be further defined. For example, it can be hypothe-
sized that patients with suppressed P-selectin expression will be
less likely to suffer a vascular event when taking antiplatelet
therapy than those whose level is not suppressed. This scenario
was seen in the small study in acute coronary syndrome, whereby
those on clopidogrel who went on to develop a further cardiovas-
cular event had higher platelet P-selectin expression than those
who had no further event (33). Equally, increased bleeding might
be associated with very suppressed P-selectin expression. This is
being studied in a larger sample of patients with recent acute
ischemic stroke or TIA who were recruited into the TARDIS trial.
Nevertheless, the relationship between assessment of platelet
function and subsequent vascular events is challenging to assess
and previous studies using other platelet function assessments
have found poor correlation between platelet function testing
and subsequent events (46).
If high platelet reactivity is related to outcomes, then a fifth
question is whether changing treatment reduces not just platelet
function but more importantly vascular events. Hence, patients
with recent cerebral ischemia and apparent resistance to clopido-
grel might best be changed to an alternative antiplatelet regimen
such as combined aspirin and clopidogrel. Trials addressing this
type of question have yet to be reported.
Sixth, the concept of de-escalation has been reported recently
whereby patients taking an expensive antiplatelet agent such as
ticagrelor or prasugrel are switched to clopidogrel for reasons of
cost or bleeding. It is then necessary to assess whether HRPR is
present in which case treatment would be reescalated to the
original antiplatelet. The TROPICAL-ACS study used this
approach with platelet function assessed using Multiplate (47).
The P-selectin approach offers a potential alternative diagnostic
for de-escalation and needs further study.
A seventh area for future research is to expand the indication
for testing platelet function. The majority of studies quoted here
have focused on vascular diseases (9,33,34,39,40) or diagnosis of
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bleeding (18). Other potential indications include assessment of
risk of bleeding prior to surgery, confirmation that platelet func-
tion is appropriately attenuated prior to invasive procedures, and
veterinary uses. However, the use of P-selectin measurement for
managing other diseases where platelets may contribute to patho-
genic processes remains untested, with examples including can-
cer, dementia, and valvular heart disease (48,49). Similarly,
pharmaceutical development may need to demonstrate that novel
agents do, or do not, have antiplatelet effects.
Finally, the studies quoted here involved a single core labora-
tory in Nottingham for flow cytometric quantification of
P-selectin expression on the surface of platelets. Flow cytometers
are widely available and there is no reason why other laboratories
should not perform these assessments, although quality control
systems would need to be set-up to ensure that results were
comparable between laboratories, as we did previously for inter-
national assessment of mean platelet volume (6).
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